MedTrace Logo

Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma

NCT05063981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-12-11

No results posted yet for this study

Summary

Understanding how Interleukin-5 blockade modulates both immune and metabolic pathways may clarify the multidimensional impact of biologic therapy in severe eosinophilic asthma. Therefore, this study aimed to assess the impact of mepolizumab on the nasal, bronchial, and systemic metabolomic profiles of consecutive patients with SEA and to explore the associations between these compartment-specific changes and clinical, inflammatory, and functional outcomes.

Conditions

  • Severe Eosinophilic Asthma

Interventions

DRUG

Mepolizumab

The effects of treatment with Mepolizumab were evaluated on clinical and laboratory markers of systemic inflammation during a 12 months follow-up period in multiple biological matrices.

Sponsors & Collaborators

  • University of Palermo

    collaborator OTHER

  • National Research Council

    collaborator UNKNOWN

  • Istituti Clinici Scientifici Maugeri SpA

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-25
Primary Completion
2023-09-29
Completion
2025-09-02
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05063981 on ClinicalTrials.gov